Kei Nakagawa

Has grant

Tohoku Medical and Pharmaceutical University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Bile cell-free DNAを用いゲノム多様性を標的にした胆道癌新規治療

Open Date: 2021-04-01

Close Date: 2024-03-31

Grant: Close

血液メタボロミクスによる胆嚢癌予後予測因子解析

Open Date: 2018-04-01

Close Date: 2021-03-31

Grant: Close

Development of a novel treatment for micro metastatic tumors derived from cholangiocarcinoma using mesenchymal stem cells

Open Date: 2013-04-01

Close Date: 2016-03-31

Grant: Close

Analysis of carcinogenic mechanism of biliary tract cancer from the protein control by ubiquitin ligase Fbw7

Open Date: 2010-01-01

Close Date: 2012-12-31

Grant: Close

Development of therapies for metastatic liver cancer with liver cells induced hibernation

Open Date: 2010-01-01

Close Date: 2011-12-31

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Takanori Morikawa

Associate Professor

Tohoku University Hospital

JAPAN

View details

Fuyuhiko Motoi

Yamagata University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kei Nakagawa

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Fecal colitis obliterans and cytomegalovirus enteritis after pancreaticoduodenectomy for resectable pancreatic cancer

Perioperative outcomes of older adult patients with pancreatic cancer based on nutritional status: a retrospective cohorat study

High preoperative Glasgow prognostic score increases a risk of hospital mortality in elderly patients with perihilar cholangiocarcinoma

GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer

Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection

Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel

Levels of tumor markers CEA/CA 19–9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer

What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma?

Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population

Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non‐metastatic disease

Collaborators (2)

Takanori Morikawa

Fuyuhiko Motoi

Make your next move.